Examkin

Question

Difficulty: HardImmunologic and Inflammatory Processes

A 48-year-old man presents to the transplant clinic with a 2-day history of decreased urine output, malaise, and mild right lower quadrant pain. He underwent a deceased-donor kidney transplantation 4 months ago for end-stage renal disease secondary to IgA nephropathy. His maintenance immunosuppressive regimen includes tacrolimus, mycophenolate mofetil, and low-dose prednisone. Vital signs show a temperature of 37.8°C (100°F) and blood pressure of 152/94 mm Hg. Physical examination reveals tenderness over the allograft in the right lower quadrant. Laboratory studies demonstrate a serum creatinine of 3.4 mg/dL, representing an acute increase from his baseline of 1.4 mg/dL obtained two weeks ago. Urinalysis shows 1+ protein and no white blood cells.

Arrange the following steps in the most appropriate chronological order for the evaluation and management of this patient's acute allograft dysfunction.

  1. 1Perform renal allograft ultrasound with Doppler and obtain a serum tacrolimus trough level
  2. 2Perform a percutaneous renal allograft biopsy
  3. 3Initiate high-dose intravenous methylprednisolone therapy
  4. 4Administer intravenous anti-thymocyte globulin (ATG)

Answer

The correct sequence is: 1) Perform renal allograft ultrasound with Doppler and obtain a serum tacrolimus trough level, 2) Perform a percutaneous renal allograft biopsy, 3) Initiate high-dose intravenous methylprednisolone therapy, 4) Administer intravenous anti-thymocyte globulin (ATG).
The evaluation of acute renal allograft dysfunction must proceed in a stepwise fashion to balance diagnostic accuracy with patient safety. The first step is to exclude pre-renal, post-renal (e.g., urinary obstruction, lymphocele), and vascular causes (e.g., renal artery thrombosis), as well as calcineurin inhibitor toxicity, using non-invasive methods like renal Doppler ultrasound and tacrolimus trough levels. Once these are excluded, a percutaneous allograft biopsy is required to establish a definitive histopathologic diagnosis. This differentiates acute cellular rejection (ACR) from antibody-mediated rejection or opportunistic infection (e.g., BK polyomavirus). After ACR is confirmed, high-dose intravenous corticosteroids (e.g., pulse methylprednisolone) are administered as first-line therapy. If the rejection proves refractory to corticosteroids, or if the initial biopsy demonstrates severe Grade III rejection with extensive vascular involvement, second-line therapy with a lymphocyte-depleting agent such as anti-thymocyte globulin (ATG) is indicated.

Step-by-Step Solution

1
Select the most appropriate initial non-invasive evaluation.
Perform renal allograft ultrasound with Doppler and obtain a tacrolimus trough level.
Before invasive procedures or potent immunosuppressants are utilized, mechanical complications (e.g., obstruction, thrombosis, lymphocele) and calcineurin inhibitor toxicity must be ruled out.
2
Determine the next diagnostic step after excluding structural/toxic causes.
Perform a percutaneous renal allograft biopsy.
A definitive tissue diagnosis is required to distinguish acute cellular rejection from antibody-mediated rejection or infectious causes (such as BK virus nephropathy), which have drastically different treatments.
3
Identify the first-line therapy once acute cellular rejection is confirmed.
Initiate high-dose intravenous methylprednisolone therapy.
Pulse corticosteroids are the initial treatment of choice for acute cellular rejection to rapidly suppress the T-cell mediated inflammatory response.
4
Select the appropriate therapy for cases that fail initial management.
Administer intravenous anti-thymocyte globulin (ATG).
If the rejection does not respond to corticosteroids, escalating therapy with a T-cell depleting agent is necessary to salvage the allograft.

Key Concept

The sequential management of acute renal allograft dysfunction involves initial non-invasive testing to rule out mechanical and toxic etiologies, followed by an allograft biopsy for definitive diagnosis, treatment with first-line pulse corticosteroids for cellular rejection, and escalation to lymphocyte-depleting agents for refractory cases.
Rate this question

Topics

Immunologic and Inflammatory Processes

More questions from this topic